Down 21% on Nov 4, and still 26% under its Nov 3 close.
−2Long-term trend
CGEM's Quality Score fell 1 point on Tue, Nov 10, to -6. It did not trade higher than the day before.
Follow CGEM's trial news. Pro members can get an alert when Cullinan Therapeutics files news, and see its trials, share raises, and its CEO's filings.
We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.
| Holding it back | Moves 11.1% a day with no profit behind it |
| Its score | Down:Lowest Quality Score since Apr 2025 |
| Latest filing | 8-K, Nov 10 |
ReportThis morning: the results are out. Past reports ›
Wed Nov 4Cullinan Therapeutics to present drug data at ASH meeting in December
CGEM closed +2.1% that day.
Tue Nov 10: Stifel Healthcare Conference 2026Investor conference · date confirmed.
Expected to report Thu Jan 7, before the open
2 more dates ahead: conferences, for Pro members.
The company says its cash lasts into 2029 (8-K, Nov 10).
Chief Scientific Officer Jennifer Michaelson sold 4,000 shares on Nov 5, under a planned sale. 17 more insider trades this year.
Decision dates and advisory committee meetings the companies have announced in their filings, soonest first and small companies first.
CGEM is #223 of 281 by Quality Score.
| Rank | Stock | Quality Score |
|---|---|---|
| 1 | ||
| 2 | ||
| 3 | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| 223 |
Expected to report Thu Jan 7, before the open (in 58 days).
What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.
The figures are not read from the release yet.
CGEM's results filing gives no sales by line in a table we read.
No outlook figures read from this release.
“Cullinan expects its cash resources to provide runway into 2029 under its current operating plan.”
From its results filing (SEC filing · Nov 10)
| Reported | Gap | Reaction | 5 days |
|---|---|---|---|
| Nov 10, 2026 | -0.2% | -4.3% | not yet |
| Aug 6, 2026 | +0.3% | +1.9% | +11.3% |
| May 7, 2026 | +0.9% | -1.8% | +8.9% |
RSI 33.1, MACD below signal, below both averages. Not scored.
Officers and directors with a Form 4 in the last 12 months.
In ETFs: CGEM is under 0.1% of VTI, the most of the 24 funds Breakaway covers, by their holdings as filed for Jun 30, 2026.
Cullinan Therapeutics Inc is a clinical-stage biopharmaceutical company developing therapies for autoimmune diseases and cancer. Its development pipeline comprises the following drug candidates: CLN-978, a CD19xCD3 bispecific T cell engager that is being developed for autoimmune diseases; CLN-049, a FLT3xCD3 bispecific T cell engager being evaluated in an ongoing clinical trial in patients with relapsed/refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS); Velinotamig, a BCMAxCD3 bispecific T cell engager being developed to counter autoimmune diseases; and Zipalertinib, being developed as a treatment for non-small cell lung cancer. Additionally, the company is developing several preclinical programs in autoimmune diseases and oncology.
“The biotechnology and pharmaceutical industries are characterized by the rapid evolution of technologies and understanding of disease etiology, intense competition and a strong emphasis on intellectual property.”
CGEM scores -6 today, which Breakaway calls Poor. It is #223 of 281 in Biotech by Quality Score, with 0 of 14 chart checks firing. Down 21% on Nov 4, and still 26% under its Nov 3 close. Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.
CGEM scores -6 today, which Breakaway calls Poor (below zero). That is #223 of 281 in Biotech by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind CGEM's -6.
Expected to report Thu Jan 7, before the open, a date Breakaway expects from the company's usual timing; the company has not confirmed it. CGEM closed higher after 1 of its last 4 reports. Past behavior, not a forecast.
Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.
Insider and Congress trades, the chart, and the financials, in one score.
See it live, free until Thursday morning. No account. No card. Then keep going with a free account.